Diabetic ulcer peptide therapy - Issar Pharma

Next Previous
Drug Profile

Diabetic ulcer peptide therapy - Issar Pharma

Latest Information Update: 24 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Issar Pharma
  • Class Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic foot ulcer

Most Recent Events

  • 24 Oct 2016 Phase-II clinical trials in Diabetic foot ulcer in India (Topical) before October 2016 (Issar Pharmaceuticals pipeline, October 2016)
  • 28 Apr 2016 Diabetic ulcer peptide therapy - Issar Pharma is available for licensing as of 28 Apr 2016. http://issar.co.in/
  • 28 Apr 2016 Phase-I clinical trials in Diabetic foot ulcer in India (Topical) prior to April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top